Abstract
Restless leg syndrome (RLS) is a common disorder, frequently of unclear origin, which is often associated with significant distress. There are a few case reports of atypical antipsychotic agents (AAP) causing RLS. The pathophysiological mechanisms resulting in emergence of these movements suggest central dopaminergic dysfunction. Dopamine agonists and L-dopa reduce the symptoms of RLS, and some agents that block the dopaminergic system aggravate RLS. Genetic influences are implicated in RLS and an association between gene polymorphisms and antipyschotic-associated onset of RLS has been postulated. Greater awareness of potential causes of RLS, and its differentiation from akathisia and illness related agitation might help in reducing the distress associated with it and improving patient compliance in patients using atypical antipsychotic agents.
Keywords: Atypical antipsychotic agents, dopamine, restless leg syndrome.
Current Drug Safety
Title:Restless Leg Syndrome Associated with Atypical Antipsychotics: Current Status, Pathophysiology, and Clinical Implications
Volume: 10 Issue: 2
Author(s): Shilpa Aggarwal, Seetal Dodd and Michael Berk
Affiliation:
Keywords: Atypical antipsychotic agents, dopamine, restless leg syndrome.
Abstract: Restless leg syndrome (RLS) is a common disorder, frequently of unclear origin, which is often associated with significant distress. There are a few case reports of atypical antipsychotic agents (AAP) causing RLS. The pathophysiological mechanisms resulting in emergence of these movements suggest central dopaminergic dysfunction. Dopamine agonists and L-dopa reduce the symptoms of RLS, and some agents that block the dopaminergic system aggravate RLS. Genetic influences are implicated in RLS and an association between gene polymorphisms and antipyschotic-associated onset of RLS has been postulated. Greater awareness of potential causes of RLS, and its differentiation from akathisia and illness related agitation might help in reducing the distress associated with it and improving patient compliance in patients using atypical antipsychotic agents.
Export Options
About this article
Cite this article as:
Aggarwal Shilpa, Dodd Seetal and Berk Michael, Restless Leg Syndrome Associated with Atypical Antipsychotics: Current Status, Pathophysiology, and Clinical Implications, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/1574886309666140527114159
DOI https://dx.doi.org/10.2174/1574886309666140527114159 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions
CNS & Neurological Disorders - Drug Targets Recent Patents on Cell-based Approaches for Intervertebral Disc Regeneration
Recent Patents on Biomedical Engineering (Discontinued) Editorial [Hot Topic: The Administration of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Dentistry (Executive Editor: Saynur Vardar)]
Current Pharmaceutical Design Neurodegeneration with Dementia: From Fundamentals of Pathology to Clinical Imaging by MRI and SPECT.
Current Medical Imaging MiR-34a Inhibits Spinal Cord Injury and Blocks Spinal Cord Neuron Apoptosis by Activating Phatidylinositol 3-kinase (PI3K)/AKT Pathway Through Targeting CD47
Current Neurovascular Research Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Pharmacological Neuroprotective Therapy for Acute Spinal Cord Injury: State of the Art
Mini-Reviews in Medicinal Chemistry Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Symptomatic Improvement, Increased Life-Span and Sustained Cell Homing in Amyotrophic Lateral Sclerosis After Transplantation of Human Umbilical Cord Blood Cells Genetically Modified with Adeno-Viral Vectors Expressing a Neuro-Protective Factor and a Neural Cell Adhesion Molecule
Current Gene Therapy Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Cell Based-Gene Delivery Approaches for the Treatment of Spinal Cord Injury and Neurodegenerative Disorders
Current Stem Cell Research & Therapy Biopolymer-based Scaffolds for Tissue Engineering Applications
Current Drug Targets 5 Hz Repetitive Transcranial Magnetic Stimulation with Maximum Voluntary Muscle Contraction Facilitates Cerebral Cortex Excitability of Normal Subjects
CNS & Neurological Disorders - Drug Targets Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase
Current Medicinal Chemistry Autonomic Nervous System Alterations in Rett Syndrome
Current Pediatric Reviews